BMJ 2020; 370 DOI: https://doi.org/10.1136/bmj.m3342 (Published 23 September 2020) Kristian B Filion, Lisa M Lix, Oriana HY Yu, Sophie Dell’Aniello, Antonios Douros, Baiju R Shah, Audray St-Jean, Anat Fisher, Eric Tremblay, Shawn C Bugden, Silvia Alessi-Severini, Paul E Ronksley, Nianping Hu, Colin R Dormuth, Pierre Ernst, Samy Suissa, on behalf of the Canadian Network for Observational Drug … [Read more...]
PharmacoEpidemiology Group (PEG) conducts research in the areas prescription drug utilization, epidemiological research methods, evaluation of drug policy and educational interventions, and drug safety and effectiveness. Selected journal articles and reports co-authored by PEG members are listed below.
Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study
Diabetes Care Aug 2020, dc200267; DOI: 10.2337/dc20-0267 Oriana Hoi Yun Yu, Sophie Dell’Aniello, Baiju R. Shah, Vanessa C. Brunetti, Jean-Marc Daigle, MichaelFralick, Antonios Douros, Nianping Hu, Silvia Alessi-Severini, Anat Fisher, Shawn C. Bugden, Paul E.Ronksley, Kristian B. Filion, Pierre Ernst, Lisa M. Lix for the Canadian Network for Observational Drug Effect Studies (CNODES) … [Read more...]
Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
Annals of Internal Medicine 2020 July 28. DOI: 10.7326/M20-0289 Antonios Douros, MD, PhD; Lisa M. Lix, PhD; Michael Fralick, MD, PhD; Sophie Dell’Aniello, MSc; Baiju R. Shah, MD, PhD; Paul E. Ronksley, PhD; Eric Tremblay, BPharm, MSc; Nianping Hu, PhD; Silvia Alessi-Severini, PhD; Anat Fisher, MD, PhD; Shawn C. Bugden, PharmD, MSc; Pierre Ernst, MD, MSc; and Kristian B. Filion, PhD; for the … [Read more...]
Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia—An interim report
Pharmacoepidemiol Drug Saf. 2020;1–8. First published: 28 May 2020. Fisher A, Kim JD, Dormuth CR Purpose: We explored changes in health services utilization associated with the Biosimilars Initiative introduced in British Columbia on May 27, 2019. To maintain drug coverage, the policy requires users of originator infliximab or etanercept to transition to biosimilar versions. We present a … [Read more...]
Sodium‐glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis – A Multi‐site Prevalent New‐user Cohort Study
First published: 08 May 2020 Abstract AIMS The United States Food and Drug Administration has warned of an increased risk of serious urinary tract infection (UTI) and Fournier’s gangrene in patients with diabetes mellitus type 2 treated with sodium–glucose cotransporter 2 inhibitors (SGLT2i). However, evidence on these risks is limited. We aimed to compare urosepsis rates in SGLT2i users with … [Read more...]
Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators
BMJ 2020; 369:m1107 (Published 29 April 2020) DOI: https://doi.org/10.1136/bmj.m1107 Key messages Sodium glucose co-transporter-2 (SGLT2) inhibitors came to market amid heightened concern over the safety of diabetes drugs The drugs have received several serious safety warnings since approval, but the number, timeliness, and strength of these safety communications have differed … [Read more...]
New Publications from the TI PharmacoEpidemiology Group
We are highlighting 2 recent articles published by members of the PharmacoEpidemiology Group (PEG) of the Therapeutics Initiative: Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System … [Read more...]
A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia
Dormuth CR, Fisher A, Carney G Pharmacoepidemiology & Drug Safety. 2020 https://doi.org/10.1002/pds.4957 Abstract Purpose: To describe a rapid monitoring plan to assess the impacts of a shift in drug coverage for biosimilar drugs in British Columbia following the introduction of a new policy on 27 May 2019. The Biosimilars Initiative requires users of originator infliximab or … [Read more...]
Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non‐depressed adults: a retrospective cohort study
Carney G, Bassett K, Maclure M, Taylor S, Dormuth CR Addiction. 2020 https://doi.org/10.1111/add.14951 Abstract Background and aims: Pharmacotherapies for smoking cessation are widely prescribed, despite substantial concerns being raised regarding the potential increased risk of cardiovascular (CV) and neuropsychiatric adverse events associated with these treatments. This study aimed to … [Read more...]
Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study
Daneman N, Chateau D, Dahl M, Zhang J, Fisher A, Sketris IS, Quail J, Marra F, Ernst P, Bugden S, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators Clinical Microbiology and Infection. 2019 https://doi.org/10.1016/j.cmi.2019.10.016 Abstract Objectives: The United States Food & Drug Administration released an advisory in 2016 that fluoroquinolones be … [Read more...]
- 1
- 2
- 3
- …
- 8
- Next Page »
